Evidence map›Paper›PMID 38124529›Full record

ArticleInternational journal of epidemiology2024

Causal relationships between risk of venous thromboembolism and 18 cancers: a bidirectional Mendelian randomization analysis.

Naomi Cornish, Philip Haycock, Hermann Brenner, Jane C Figueiredo, Tessel E Galesloot, Robert C Grant, Mattias Johansson, Daniela Mariosa, James McKay, Rish Pai and 10 more

Open access · hybridAbstract read
In one paragraph

Article in International journal of epidemiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 13 institutions in 6 countries.

Naomi CornishSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.ORCID 0000-0002-7827-869X
Philip HaycockMedical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, UK.ORCID 0000-0001-5001-3350
Hermann BrennerDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Jane C FigueiredoDepartment of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0001-8040-3341
Tessel E GaleslootDepartment for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.
Robert C GrantDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Mattias JohanssonInternational Agency for Research on Cancer, World Health Organization, Lyon, France.
Daniela MariosaInternational Agency for Research on Cancer, World Health Organization, Lyon, France.ORCID 0000-0001-8181-1419
James McKayInternational Agency for Research on Cancer, World Health Organization, Lyon, France.
Rish PaiDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ, USA.
Andrew J PellattDivision of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA.
N Jewel SamadderDivision of Gastroenterology, Mayo Clinic, Phoenix, AZ, USA.
Jianxin ShiDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Florian ThibordPopulation Sciences Branch, Division of Intramural Research, National Heart, Lung and Blood Institute, Framingham, MA, USA.
David-Alexandre TrégouëtUniversity of Bordeaux, Bordeaux Population Health Research Center, Bordeaux, France.
Catherine VoegeleInternational Agency for Research on Cancer, World Health Organization, Lyon, France.
Chrissie ThirlwellUniversity of Exeter Medical School, University of Exeter, Exeter, UK.ORCID 0000-0003-3962-5780
Andrew MumfordSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
Ryan LangdonMedical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
InterLymph Consortium, INVENT-MVP Consortium
Centre international de recherche sur le cancer · FRUniversity of Bristol · GBUniversity of Exeter · GBCedars-Sinai Medical Center · USGerman Cancer Research Center · DEMayo Clinic Hospital · USMayo Clinic in Arizona · USNational Heart Lung and Blood Institute · USNational Institutes of Health · USRadboud University Nijmegen · NLThe University of Texas MD Anderson Cancer Center · USUniversité de Bordeaux · FRUniversity Health Network · CA

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Translating Molecular and Clinical Data to Population Lung Cancer Risk AssessmentU19CA203654 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Christopher I. Amos, Rayjean J. Hung · 2017 to 2026
$23.7M
Data sharing: the Colon Cancer Family Registry CohortU01CA167551 · NCI · UNIVERSITY OF MELBOURNE · PI Daniel David BUCHANAN, Steven Gallinger · 2018 to 2026
$16.8M
Genetic Epidermiology of MelanomaR01CA083115 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BISHOP, DAVID TIMOTHY, ELDER, DAVID ERIC · 2001 to 2017
$13.0M
Detection of Colorectal Cancer Susceptibility Loci Using Genome-Wide SequencingU01CA164930 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETERS, ULRIKE · 2012 to 2015
$12.4M
Genome-Wide Association Study of Nonsynonymous SNPs in Colon CancerR01CA059045 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETERS, ULRIKE · 1994 to 2011
$11.5M
Epidemiologic StudiesU19CA148065 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI AHSAN, HABIBUL, BRUGGE, JOAN SIEFERT · 2010 to 2014
$10.6M
Epidemiological and Clinical Translational Studies Post Genome-Wide AssociationU19CA148537 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI EASTON, DOUGLAS FREDERICK, EELES, ROSALIND · 2010 to 2014
$10.4M
Ovarian cancer GWAS discovery, expansion and replication (N2 - Project #1)U19CA148112 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SELLERS, THOMAS A · 2010 to 2014
$10.2M
Using Functional Genomics to Inform Gene Environment Interactions for Colorectal CancerR01CA201407 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI CASEY, GRAHAM, GAUDERMAN, WILLIAM JAMES · 2016 to 2020
$9.6M
A genome-wide association study for breast cancer in BRCA1 mutation carriersR01CA128978 · NCI · MAYO CLINIC ROCHESTER · PI COUCH, FERGUS JOSEPH · 2008 to 2012
$4.8M
Pooled genome-wide analysis of kidney cancer riskU01CA155309 · NCI · INTERNATIONAL AGENCY FOR RES ON CANCER · PI SCELO, GHISLAINE · 2011 to 2014
$3.7M
Cancer Research UK 29019Cancer Research UK C12292/A11174Cancer Research UK C12292/A20861Cancer Research UK C1281/A12014Cancer Research UK C1287/A10118Cancer Research UK C1287/A10710Cancer Research UK C1287/A16563Cancer Research UK C18281/A2901Cancer Research UK C5047/A10692Cancer Research UK C5047/A15007Cancer Research UK C5047/A8384Cancer Research UK C588/A10589Cancer Research UK C588/A4994Cancer Research UK C8197/A16565Cancer Research UK C8216/A6129Cancer Research UK PPRPGM-NOV20\100002NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA059045NCI NIH HHS R01 CA083115NCI NIH HHS R01 CA128978NCI NIH HHS R01 CA201407NCI NIH HHS R01 CA244588NCI NIH HHS U01 CA155309NCI NIH HHS U01 CA164930NCI NIH HHS U01 CA167551NCI NIH HHS U01 CA257679NCI NIH HHS U19 CA148065NCI NIH HHS U19 CA148112NCI NIH HHS U19 CA148537NCI NIH HHS U19 CA203654NIH HHS S10 OD028685Wellcome TrustWellcome Trust 225541/Z/22/ZWorld Health Organization 001
6 · The paper itself

Abstract

backgroundPeople with cancer experience high rates of venous thromboembolism (VTE). Risk of subsequent cancer is also increased in people experiencing their first VTE. The causal mechanisms underlying this association are not completely understood, and it is unknown whether VTE is itself a risk factor for cancer.

methodsWe used data from large genome-wide association study meta-analyses to perform bidirectional Mendelian randomization analyses to estimate causal associations between genetic liability to VTE and risk of 18 different cancers.

resultsWe found no conclusive evidence that genetic liability to VTE was causally associated with an increased incidence of cancer, or vice versa. We observed an association between liability to VTE and pancreatic cancer risk [odds ratio for pancreatic cancer: 1.23 (95% confidence interval: 1.08-1.40) per log-odds increase in VTE risk, P = 0.002]. However, sensitivity analyses revealed this association was predominantly driven by a variant proxying non-O blood group, with inadequate evidence to suggest a causal relationship.

conclusionsThese findings do not support the hypothesis that genetic liability to VTE is a cause of cancer. Existing observational epidemiological associations between VTE and cancer are therefore more likely to be driven by pathophysiological changes which occur in the setting of active cancer and anti-cancer treatments. Further work is required to explore and synthesize evidence for these mechanisms.

Indexed as

Pancreatic NeoplasmsVenous ThromboembolismGenome-Wide Association StudyHumansMendelian Randomization AnalysisRisk Factorsdeep vein thrombosisgenetic epidemiologymalignancyMendelian randomizationpulmonary embolus

Identifiers

PMID38124529
PMCPMC10859161
OpenAlexW4390063132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.